MAY 10, 2020 4:51 PM PDT

Antiviral Drug Treats Naso-Pharyngeal Cancer

WRITTEN BY: Nouran Amin

Scientists at Hong Kong Baptist University (HKBU) developed a novel anti-Epstein-Barr virus (EBV) drug that can shrink tumors caused by the EBV virus. It is the first known agent to successfully target the virus and disturb its latency in tumor cells in this way.

EBV infection spreads through close to close person contact and has infected more than 90% of the human population worldwide.

Learn more about the EBV virus and cancer:

Now, findings published in the journal Proceedings of the National Academy of Sciences found that potently reactivating the EBV from latency can be a form of nasopharyngeal carcinoma (NPC) therapeutic.  The drug works by binding and disrupting the vital EBV protein.

"This discovery lays a good foundation for the development of therapeutics for the treatment of EBV-associated diseases such as NPC," said Professor Gary Wong Ka-Leung.

Source: Science Daily

About the Author
  • Nouran is a scientist, educator, and life-long learner with a passion for making science more communicable. When not busy in the lab isolating blood macrophages, she enjoys writing on various STEM topics.
You May Also Like
MAR 09, 2021
Drug Discovery & Development
Personalized Psychedelic Assisted-Therapy
MAR 09, 2021
Personalized Psychedelic Assisted-Therapy
Psychedelics have long been known for their therapeutic in treating mental health disorders. However, there remains a co ...
APR 05, 2021
Drug Discovery & Development
Scientists Regenerate Missing Teeth in Mice
APR 05, 2021
Scientists Regenerate Missing Teeth in Mice
While most people have 32 teeth, around 1% of the population has more or fewer due to congenital reasons. Now, researche ...
APR 17, 2021
Drug Discovery & Development
Facebook AI May Speed up Cancer Drug Discovery
APR 17, 2021
Facebook AI May Speed up Cancer Drug Discovery
Facebook has claimed that its new artificial intelligence, known as 'Compositional Perturbation Autoencoder' (CP ...
APR 22, 2021
Drug Discovery & Development
mRNA Covid Vaccines May Protect Against New Strains and Common Cold
APR 22, 2021
mRNA Covid Vaccines May Protect Against New Strains and Common Cold
Researchers from Johns Hopkins have found that the mRNA Covid vaccines developed by Pfizer and Moderna not only work wit ...
MAY 27, 2021
Neuroscience
Research Less Likely to Be True is Cited More
MAY 27, 2021
Research Less Likely to Be True is Cited More
Researchers from the University of California San Diego have found that non-replicable data is cited 153 times more ofte ...
JUN 03, 2021
Immunology
Inhalable Anti-COVID Nanobodies Show Promising Results in Hamsters
JUN 03, 2021
Inhalable Anti-COVID Nanobodies Show Promising Results in Hamsters
Nanobodies are small fragments of monoclonal antibodies that from a therapeutic perspective are more stable and cheaper ...
Loading Comments...